Prevent Biometrics has released a 2.0 version of its sensor-embedded mouthguard to monitor head impacts that’s 60% smaller than the incumbent product. The product launch comes as Prevent Biometrics is providing its smart mouthguards to women’s national team rugby players during the ongoing World Cup in New Zealand.

LOS GATOS, CA – September 19th, 2022 – Advanced NanoTherapies, Inc., a privately-held medical device company committed to solving vascular disease’s most significant challenges through the creative applications of nanotechnology, today announced the U.S. Food and Drug Administration (FDA) has granted the company a Breakthrough Device designation for its SirPlux Duo Drug-Coated Balloon (DCB) for coronary artery disease in vessels less than 3.0mm. This achievement comes only weeks after the company received two other critical Breakthrough Device designations for its SirPlux Duo DCB in coronary in-stent restenosis (ISR) and peripheral below-the-knee (BTK) lesions.

Findings from a Cleveland Clinic-led trial show that a Cerebral Embolic Protection (CEP) device reduced the risk of disabling strokes by capturing and removing tiny pieces of calcium and other fragments resulting from transcatheter aortic valve replacement (TAVR) before they can reach the brain.